An IL-17–dominant immune profile is shared across the major orphan forms of ichthyosis

Journal of Allergy and Clinical Immunology

Volumn 139, Issue 1, 2017, Pages 152-165

  Paller, Amy S ^a   Renert Yuval, Yael ^b   Suprun, Maria ^b   Esaki, Hitokazu ^b,c   Oliva, Margeaux ^b   Huynh, Thy Nhat ^a   Ungar, Benjamin ^c   Kunjravia, Norma ^c   Friedland, Rivka ^a   Peng, Xiangyu ^b   Zheng, Xiuzhong ^c   Estrada, Yeriel D ^b   Krueger, James G ^b   Choate, Keith A ^d   Suárez Fariñas, Mayte ^b,c   Guttman Yassky, Emma ^b,c  

^a NORTHWESTERN UNIVERSITY   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c ROCKEFELLER UNIVERSITY   (United States)

^d YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

autosomal recessive congenital ichthyosis; congenital ichthyosiform erythroderma; Epidermis; epidermolytic ichthyosis; ichthyosis; IL 17; inflammation; lamellar ichthyosis; Netherton syndrome; skin; TNF

Indexed keywords

CXCL1 CHEMOKINE; CYTOKERATIN 16; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 19; INTERLEUKIN 1BETA; INTERLEUKIN 2; INTERLEUKIN 31; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; TUMOR NECROSIS FACTOR; INTERLEUKIN 23; MESSENGER RNA;

ADOLESCENT; ADULT; ARTICLE; ATOPIC DERMATITIS; CHILD; CLINICAL ARTICLE; CLINICAL FEATURE; CONGENITAL ICHTHYOSIFORM ERYTHRODERMA; CONTROLLED STUDY; CORRELATIONAL STUDY; DENDRITIC CELL; EPIDERMIS HYPERPLASIA; EPIDERMOLYTIC ICHTHYOSIS; FEMALE; GENE EXPRESSION; HUMAN; HUMAN TISSUE; ICHTHYOSIS; ICHTHYOSIS AREA SEVERITY INDEX; IMMUNOHISTOCHEMISTRY; LAMELLAR ICHTHYOSIS; LYMPHOCYTIC INFILTRATION; MALE; NETHERTON DISEASE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSORIASIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN DISEASE ASSESSMENT; SKIN WATER LOSS; SKINFOLD THICKNESS; T LYMPHOCYTE; AGED; GENETICS; IMMUNOLOGY; METABOLISM; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SKIN; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; CHILD; DERMATITIS, ATOPIC; FEMALE; GENE EXPRESSION; HUMANS; ICHTHYOSIS; INTERLEUKIN-17; INTERLEUKIN-23; MALE; MIDDLE AGED; PSORIASIS; RNA, MESSENGER; SEVERITY OF ILLNESS INDEX; SKIN; YOUNG ADULT;

EID: 84996480060     PISSN: 00916749     EISSN: 10976825     Source Type: Journal    
DOI: 10.1016/j.jaci.2016.07.019     Document Type: Article

References (126)

1. 1 Oji, V., Tadini, G., Akiyama, M., Blanchet Bardon, C., Bodemer, C., Bourrat, E., et al. Revised nomenclature and classification of inherited ichthyoses: results of the First Ichthyosis Consensus Conference in Soreze 2009. J Am Acad Dermatol 63 (2010), 607–641.
2. 2 DiGiovanna, J.J., Robinson-Bostom, L., Ichthyosis: etiology, diagnosis, and management. Am J Clin Dermatol 4 (2003), 81–95.
3. 3 Oji, V., Traupe, H., Ichthyoses: differential diagnosis and molecular genetics. Eur J Dermatol 16 (2006), 349–359.
4. 4 Craig, W.Y., Roberson, M., Palomaki, G.E., Shackleton, C.H., Marcos, J., Haddow, J.E., Prevalence of steroid sulfatase deficiency in California according to race and ethnicity. Prenat Diagn 30 (2010), 893–898.
5. 5 Traupe, H., Fischer, J., Oji, V., Nonsyndromic types of ichthyoses—an update. J Dtsch Dermatol Ges 12 (2014), 109–121.
6. 6 Briot, A., Deraison, C., Lacroix, M., Bonnart, C., Robin, A., Besson, C., et al. Kallikrein 5 induces atopic dermatitis-like lesions through PAR2-mediated thymic stromal lymphopoietin expression in Netherton syndrome. J Exp Med 206 (2009), 1135–1147.
7. 7 Thyssen, J.P., Godoy-Gijon, E., Elias, P.M., Ichthyosis vulgaris: the filaggrin mutation disease. Br J Dermatol 168 (2013), 1155–1166.
8. 8 Ganemo, A., Lindholm, C., Lindberg, M., Sjoden, P.O., Vahlquist, A., Quality of life in adults with congenital ichthyosis. J Adv Nurs 44 (2003), 412–419.
9. 9 Dreyfus, I., Pauwels, C., Bourrat, E., Bursztejn, A.C., Maruani, A., Chiaverini, C., et al. Burden of inherited ichthyosis: a French national survey. Acta Derm Venereol 95 (2015), 326–328.
10. 10 Williams, M.L., Ichthyosis: mechanisms of disease. Pediatr Dermatol 9 (1992), 365–368.
11. 11 Elias, P.M., Williams, M.L., Holleran, W.M., Jiang, Y.J., Schmuth, M., Pathogenesis of permeability barrier abnormalities in the ichthyoses: inherited disorders of lipid metabolism. J Lipid Res 49 (2008), 697–714.
12. 12 Eckl, K.M., Weindl, G., Ackermann, K., Kuchler, S., Casper, R., Radowski, M.R., et al. Increased cutaneous absorption reflects impaired barrier function of reconstructed skin models mimicking keratinisation disorders. Exp Dermatol 23 (2014), 286–288.
13. 13 Hernandez-Martin, A., Aranegui, B., Martin-Santiago, A., Garcia-Doval, I., A systematic review of clinical trials of treatments for the congenital ichthyoses, excluding ichthyosis vulgaris. J Am Acad Dermatol 69 (2013), 544–549.e8.
14. 14 Vahlquist, A., Ganemo, A., Virtanen, M., Congenital ichthyosis: an overview of current and emerging therapies. Acta Derm Venereol 88 (2008), 4–14.
15. 15 Fleckman, P., Management of the ichthyoses. Skin Therapy Lett 8 (2003), 3–7.
16. 16 Digiovanna, J.J., Mauro, T., Milstone, L.M., Schmuth, M., Toro, J.R., Systemic retinoids in the management of ichthyoses and related skin types. Dermatol Ther 26 (2013), 26–38.
17. 17 Halverstam, C.P., Vachharajani, A., Mallory, S.B., Cushing syndrome from percutaneous absorption of 1% hydrocortisone ointment in Netherton syndrome. Pediatr Dermatol 24 (2007), 42–45.
18. 18 Allen, A., Siegfried, E., Silverman, R., Williams, M.L., Elias, P.M., Szabo, S.K., et al. Significant absorption of topical tacrolimus in 3 patients with Netherton syndrome. Arch Dermatol 137 (2001), 747–750.
19. 19 Descargues, P., Deraison, C., Bonnart, C., Kreft, M., Kishibe, M., Ishida-Yamamoto, A., et al. Spink5-deficient mice mimic Netherton syndrome through degradation of desmoglein 1 by epidermal protease hyperactivity. Nat Genet 37 (2005), 56–65.
20. 20 Furio, L., de Veer, S., Jaillet, M., Briot, A., Robin, A., Deraison, C., et al. Transgenic kallikrein 5 mice reproduce major cutaneous and systemic hallmarks of Netherton syndrome. J Exp Med 211 (2014), 499–513.
21. 21 Furio, L., Pampalakis, G., Michael, I.P., Nagy, A., Sotiropoulou, G., Hovnanian, A., KLK5 inactivation reverses cutaneous hallmarks of Netherton syndrome. PLoS Genet, 11, 2015, e1005389.
22. 22 O'Shaughnessy, R.F., Choudhary, I., Harper, J.I., Interleukin-1 alpha blockade prevents hyperkeratosis in an in vitro model of lamellar ichthyosis. Hum Mol Genet 19 (2010), 2594–2605.
23. 23 Jensen, J.M., Schutze, S., Neumann, C., Proksch, E., Impaired cutaneous permeability barrier function, skin hydration, and sphingomyelinase activity in keratin 10 deficient mice. J Invest Dermatol 115 (2000), 708–713.
24. 24 Roth, W., Kumar, V., Beer, H.D., Richter, M., Wohlenberg, C., Reuter, U., et al. Keratin 1 maintains skin integrity and participates in an inflammatory network in skin through interleukin-18. J Cell Sci 125 (2012), 5269–5279.
25. 25 Rosenberger, S., Dick, A., Latzko, S., Hausser, I., Stark, H.J., Rauh, M., et al. A mouse organotypic tissue culture model for autosomal recessive congenital ichthyosis. Br J Dermatol 171 (2014), 1347–1357.
26. 26 Krieg, P., Rosenberger, S., de Juanes, S., Latzko, S., Hou, J., Dick, A., et al. Aloxe3 knockout mice reveal a function of epidermal lipoxygenase-3 as hepoxilin synthase and its pivotal role in barrier formation. J Invest Dermatol 133 (2013), 172–180.
27. 27 Zuo, Y., Zhuang, D.Z., Han, R., Isaac, G., Tobin, J.J., McKee, M., et al. ABCA12 maintains the epidermal lipid permeability barrier by facilitating formation of ceramide linoleic esters. J Biol Chem 283 (2008), 36624–36635.
28. 28 Smyth, I., Hacking, D.F., Hilton, A.A., Mukhamedova, N., Meikle, P.J., Ellis, S., et al. A mouse model of harlequin ichthyosis delineates a key role for Abca12 in lipid homeostasis. PLoS Genet, 4, 2008, e1000192.
29. 29 Aufenvenne, K., Rice, R.H., Hausser, I., Oji, V., Hennies, H.C., Rio, M.D., et al. Long-term faithful recapitulation of transglutaminase 1-deficient lamellar ichthyosis in a skin-humanized mouse model, and insights from proteomic studies. J Invest Dermatol 132 (2012), 1918–1921.
30. 30 Briot, A., Lacroix, M., Robin, A., Steinhoff, M., Deraison, C., Hovnanian, A., Par2 inactivation inhibits early production of TSLP, but not cutaneous inflammation, in Netherton syndrome adult mouse model. J Invest Dermatol 130 (2010), 2736–2742.
31. 31 Cottle, D.L., Ursino, G.M., Ip, S.C., Jones, L.K., Ditommaso, T., Hacking, D.F., et al. Fetal inhibition of inflammation improves disease phenotypes in harlequin ichthyosis. Hum Mol Genet 24 (2015), 436–449.
32. 32 Descargues, P., Deraison, C., Prost, C., Fraitag, S., Mazereeuw-Hautier, J., D'Alessio, M., et al. Corneodesmosomal cadherins are preferential targets of stratum corneum trypsin- and chymotrypsin-like hyperactivity in Netherton syndrome. J Invest Dermatol 126 (2006), 1622–1632.
33. 33 Fontao, L., Laffitte, E., Briot, A., Kaya, G., Roux-Lombard, P., Fraitag, S., et al. Infliximab infusions for Netherton syndrome: sustained clinical improvement correlates with a reduction of thymic stromal lymphopoietin levels in the skin. J Invest Dermatol 131 (2011), 1947–1950.
34. 34 Yalcin, A.D., A case of Netherton syndrome: successful treatment with omalizumab and pulse prednisolone and its effects on cytokines and immunoglobulin levels. Immunopharmacol Immunotoxicol 38 (2016), 162–166.
35. 35 Pavez Lorie, E., Ganemo, A., Borgers, M., Wouters, L., Blockhuys, S., van de Plassche, L., et al. Expression of retinoid-regulated genes in lamellar ichthyosis vs. healthy control epidermis: changes after oral treatment with liarozole. Acta Derm Venereol 89 (2009), 12–20.
36. 36 Hannula-Jouppi, K., Laasanen, S.L., Ilander, M., Furio, L., Tuomiranta, M., Marttila, R., et al. Intrafamily and interfamilial phenotype variation and immature immunity in patients with Netherton syndrome and Finnish SPINK5 founder mutation. JAMA Dermatol 152 (2016), 435–442.
37. 37 de Oliveira, G.V., Hawkins, H.K., Guedes, A.C., Pinto, L.F., Oliveras, G., Kitten, G.T., et al. Comel-Netherton syndrome in brothers and expression of cytokeratins. J Am Acad Dermatol 52 (2005), 725–726.
38. 38 Konishi, T., Tsuda, T., Sakaguchi, Y., Imai, Y., Ito, T., Hirota, S., et al. Upregulation of interleukin-33 in the epidermis of two Japanese patients with Netherton syndrome. J Dermatol 41 (2014), 258–261.
39. 39 Van Gysel, D., Koning, H., Baert, M.R., Savelkoul, H.F., Neijens, H.J., Oranje, A.P., Clinico-immunological heterogeneity in Comel-Netherton syndrome. Dermatology 202 (2001), 99–107.
40. 40 Renner, E.D., Hartl, D., Rylaarsdam, S., Young, M.L., Monaco-Shawver, L., Kleiner, G., et al. Comel-Netherton syndrome defined as primary immunodeficiency. J Allergy Clin Immunol 124 (2009), 536–543.
41. 41 Hosomi, N., Fukai, K., Nakanishi, T., Funaki, S., Ishii, M., Caspase-1 activity of stratum corneum and serum interleukin-18 level are increased in patients with Netherton syndrome. Br J Dermatol 159 (2008), 744–746.
42. 42 Akagi, A., Kitoh, A., Moniaga, C.S., Fujimoto, A., Fujikawa, H., Shimomura, Y., et al. Case of Netherton syndrome with an elevated serum thymus and activation-regulated chemokine level. J Dermatol 40 (2013), 752–753.
43. 43 Lacroix, M., Lacaze-Buzy, L., Furio, L., Tron, E., Valari, M., Van der Wier, G., et al. Clinical expression and new SPINK5 splicing defects in Netherton syndrome: unmasking a frequent founder synonymous mutation and unconventional intronic mutations. J Invest Dermatol 132 (2012), 575–582.
44. 44 Lowes, M.A., Russell, C.B., Martin, D.A., Towne, J.E., Krueger, J.G., The IL-23/T17 pathogenic axis in psoriasis is amplified by keratinocyte responses. Trends Immunol 34 (2013), 174–181.
45. 45 Noda, S., Krueger, J.G., Guttman-Yassky, E., The translational revolution and use of biologics in patients with inflammatory skin diseases. J Allergy Clin Immunol 135 (2015), 324–336.
46. 46 Martin, D.A., Towne, J.E., Kricorian, G., Klekotka, P., Gudjonsson, J.E., Krueger, J.G., et al. The emerging role of IL-17 in the pathogenesis of psoriasis: preclinical and clinical findings. J Invest Dermatol 133 (2013), 17–26.
47. 47 Wang, C.Q., Suarez-Farinas, M., Nograles, K.E., Mimoso, C.A., Shrom, D., Dow, E.R., et al. IL-17 induces inflammation-associated gene products in blood monocytes, and treatment with ixekizumab reduces their expression in psoriasis patient blood. J Invest Dermatol 134 (2014), 2990–2993.
48. 48 Kamalpour, L., Rice, Z.P., Pavlis, M., Veledar, E., Chen, S.C., Reliable methods to evaluate the clinical severity of ichthyosis. Pediatr Dermatol 27 (2010), 148–153.
49. 49 Fredriksson, T., Pettersson, U., Severe psoriasis—oral therapy with a new retinoid. Dermatologica 157 (1978), 238–244.
50. 50 Noda, S., Suarez-Farinas, M., Ungar, B., Kim, S.J., de Guzman Strong, C., Xu, H., et al. The Asian atopic dermatitis phenotype combines features of atopic dermatitis and psoriasis with increased TH17 polarization. J Allergy Clin Immunol 136 (2015), 1254–1264.
51. 51 Khattri, S., Shemer, A., Rozenblit, M., Dhingra, N., Czarnowicki, T., Finney, R., et al. Cyclosporine in patients with atopic dermatitis modulates activated inflammatory pathways and reverses epidermal pathology. J Allergy Clin Immunol 133 (2014), 1626–1634.
52. 52 Johnson-Huang, L.M., Suarez-Farinas, M., Sullivan-Whalen, M., Gilleaudeau, P., Krueger, J.G., Lowes, M.A., Effective narrow-band UVB radiation therapy suppresses the IL-23/IL-17 axis in normalized psoriasis plaques. J Invest Dermatol 130 (2010), 2654–2663.
53. 53 Tintle, S., Shemer, A., Suarez-Farinas, M., Fujita, H., Gilleaudeau, P., Sullivan-Whalen, M., et al. Reversal of atopic dermatitis with narrow-band UVB phototherapy and biomarkers for therapeutic response. J Allergy Clin Immunol 128 (2011), 583–593 e1-4.
54. 54 Dhingra, N., Suarez-Farinas, M., Fuentes-Duculan, J., Gittler, J.K., Shemer, A., Raz, A., et al. Attenuated neutrophil axis in atopic dermatitis compared to psoriasis reflects TH17 pathway differences between these diseases. J Allergy Clin Immunol 132 (2013), 498–501.e3.
55. 55 Esaki, H., Ewald, D.A., Ungar, B., Rozenblit, M., Zheng, X., Xu, H., et al. Identification of novel immune and barrier genes in atopic dermatitis by means of laser capture microdissection. J Allergy Clin Immunol 135 (2015), 153–163.
56. 56 Suarez-Farinas, M., Ungar, B., Correa da Rosa, J., Ewald, D.A., Rozenblit, M., Gonzalez, J., et al. RNA sequencing atopic dermatitis transcriptome profiling provides insights into novel disease mechanisms with potential therapeutic implications. J Allergy Clin Immunol 135 (2015), 1218–1227.
57. 57 Czarnowicki, T., Gonzalez, J., Bonifacio, K.M., Shemer, A., Xiangyu, P., Kunjravia, N., et al. Diverse activation and differentiation of multiple B-cell subsets in patients with atopic dermatitis but not in patients with psoriasis. J Allergy Clin Immunol 137 (2016), 118–129.e5.
58. 58 Taieb, A., Labreze, C., Collodion baby: what's new. J Eur Acad Dermatol Venereol 16 (2002), 436–437.
59. 59 Van Gysel, D., Lijnen, R.L., Moekti, S.S., de Laat, P.C., Oranje, A.P., Collodion baby: a follow-up study of 17 cases. J Eur Acad Dermatol Venereol 16 (2002), 472–475.
60. 60 Russell, L.J., DiGiovanna, J.J., Rogers, G.R., Steinert, P.M., Hashem, N., Compton, J.G., et al. Mutations in the gene for transglutaminase 1 in autosomal recessive lamellar ichthyosis. Nat Genet 9 (1995), 279–283.
61. 61 Eckl, K.M., de Juanes, S., Kurtenbach, J., Natebus, M., Lugassy, J., Oji, V., et al. Molecular analysis of 250 patients with autosomal recessive congenital ichthyosis: evidence for mutation hotspots in ALOXE3 and allelic heterogeneity in ALOX12B. J Invest Dermatol 129 (2009), 1421–1428.
62. 62 Fischer, J., Autosomal recessive congenital ichthyosis. J Invest Dermatol 129 (2009), 1319–1321.
63. 63 Chavanas, S., Bodemer, C., Rochat, A., Hamel-Teillac, D., Ali, M., Irvine, A.D., et al. Mutations in SPINK5, encoding a serine protease inhibitor, cause Netherton syndrome. Nat Genet 25 (2000), 141–142.
64. 64 Hachem, J.P., Wagberg, F., Schmuth, M., Crumrine, D., Lissens, W., Jayakumar, A., et al. Serine protease activity and residual LEKTI expression determine phenotype in Netherton syndrome. J Invest Dermatol 126 (2006), 1609–1621.
65. 65 Elman, S., Hynan, L.S., Gabriel, V., Mayo, M.J., The 5-D itch scale: a new measure of pruritus. Br J Dermatol 162 (2010), 587–593.
66. 66 Mansouri, Y., Guttman-Yassky, E., Immune pathways in atopic dermatitis, and definition of biomarkers through broad and targeted therapeutics. J Clin Med 4 (2015), 858–873.
67. 67 Suarez-Farinas, M., Tintle, S.J., Shemer, A., Chiricozzi, A., Nograles, K., Cardinale, I., et al. Nonlesional atopic dermatitis skin is characterized by broad terminal differentiation defects and variable immune abnormalities. J Allergy Clin Immunol 127 (2011), 954–964 e1-4.
68. 68 Rice, R.H., Bradshaw, K.M., Durbin-Johnson, B.P., Rocke, D.M., Eigenheer, R.A., Phinney, B.S., et al. Distinguishing ichthyoses by protein profiling. PLoS One, 8, 2013, e75355.
69. 69 Leung, D.Y., Guttman-Yassky, E., Deciphering the complexities of atopic dermatitis: shifting paradigms in treatment approaches. J Allergy Clin Immunol 134 (2014), 769–779.
70. 70 Deraison, C., Bonnart, C., Lopez, F., Besson, C., Robinson, R., Jayakumar, A., et al. LEKTI fragments specifically inhibit KLK5, KLK7, and KLK14 and control desquamation through a pH-dependent interaction. Mol Biol Cell 18 (2007), 3607–3619.
71. 71 Guttman-Yassky, E., Suarez-Farinas, M., Chiricozzi, A., Nograles, K.E., Shemer, A., Fuentes-Duculan, J., et al. Broad defects in epidermal cornification in atopic dermatitis identified through genomic analysis. J Allergy Clin Immunol 124 (2009), 1235–1244.e58.
72. 72 Suarez-Farinas, M., Lowes, M.A., Zaba, L.C., Krueger, J.G., Evaluation of the psoriasis transcriptome across different studies by gene set enrichment analysis (GSEA). PLoS One, 5, 2010, e10247.
73. 73 Chiricozzi, A., Guttman-Yassky, E., Suarez-Farinas, M., Nograles, K.E., Tian, S., Cardinale, I., et al. Integrative responses to IL-17 and TNF-alpha in human keratinocytes account for key inflammatory pathogenic circuits in psoriasis. J Invest Dermatol 131 (2011), 677–687.
74. 74 Witte, E., Kokolakis, G., Witte, K., Philipp, S., Doecke, W.D., Babel, N., et al. IL-19 is a component of the pathogenetic IL-23/IL-17 cascade in psoriasis. J Invest Dermatol 134 (2014), 2757–2767.
75. 75 Liao, S.C., Cheng, Y.C., Wang, Y.C., Wang, C.W., Yang, S.M., Yu, C.K., et al. IL-19 induced Th2 cytokines and was up-regulated in asthma patients. J Immunol 173 (2004), 6712–6718.
76. 76 Hsing, C.H., Hsu, C.C., Chen, W.Y., Chang, L.Y., Hwang, J.C., Chang, M.S., Expression of IL-19 correlates with Th2 cytokines in uraemic patients. Nephrol Dial Transplant 22 (2007), 2230–2238.
77. 77 Gallagher, G., Eskdale, J., Jordan, W., Peat, J., Campbell, J., Boniotto, M., et al. Human interleukin-19 and its receptor: a potential role in the induction of Th2 responses. Int Immunopharmacol 4 (2004), 615–626.
78. 78 Huang, F., Wachi, S., Thai, P., Loukoianov, A., Tan, K.H., Forteza, R.M., et al. Potentiation of IL-19 expression in airway epithelia by IL-17A and IL-4/IL-13: important implications in asthma. J Allergy Clin Immunol 121 (2008), 1415–1421 e1-3.
79. 79 Nograles, K.E., Zaba, L.C., Guttman-Yassky, E., Fuentes-Duculan, J., Suarez-Farinas, M., Cardinale, I., et al. Th17 cytokines interleukin (IL)-17 and IL-22 modulate distinct inflammatory and keratinocyte-response pathways. Br J Dermatol 159 (2008), 1092–1102.
80. 80 Sonkoly, E., Muller, A., Lauerma, A.I., Pivarcsi, A., Soto, H., Kemeny, L., et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J Allergy Clin Immunol 117 (2006), 411–417.
81. 81 Cedeno-Laurent, F., Singer, E.M., Wysocka, M., Benoit, B.M., Vittorio, C.C., Kim, E.J., et al. Improved pruritus correlates with lower levels of IL-31 in CTCL patients under different therapeutic modalities. Clin Immunol 158 (2015), 1–7.
82. 82 Hewett, D.R., Simons, A.L., Mangan, N.E., Jolin, H.E., Green, S.M., Fallon, P.G., et al. Lethal, neonatal ichthyosis with increased proteolytic processing of filaggrin in a mouse model of Netherton syndrome. Hum Mol Genet 14 (2005), 335–346.
83. 83 Bonefeld, C.M., Petersen, T.H., Bandier, J., Agerbeck, C., Linneberg, A., Ross-Hansen, K., et al. Epidermal filaggrin deficiency mediates increased systemic Th17 immune response. Br J Dermatol, 2016 [Epub ahead of print].
84. 84 Papp, K.A., Langley, R.G., Lebwohl, M., Krueger, G.G., Szapary, P., Yeilding, N., et al. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 371 (2008), 1675–1684.
85. 85 Chiricozzi, A., Saraceno, R., Chimenti, M.S., Guttman-Yassky, E., Krueger, J.G., Role of IL-23 in the pathogenesis of psoriasis: a novel potential therapeutic target?. Expert Opin Ther Targets 18 (2014), 513–525.
86. 86 Hamilton, J.D., Suarez-Farinas, M., Dhingra, N., Cardinale, I., Li, X., Kostic, A., et al. Dupilumab improves the molecular signature in skin of patients with moderate-to-severe atopic dermatitis. J Allergy Clin Immunol 134 (2014), 1293–1300.
87. 87 Hamilton, J.D., Ungar, B., Guttman-Yassky, E., Drug evaluation review: dupilumab in atopic dermatitis. Immunotherapy 7 (2015), 1043–1058.
88. 88 Beck, L.A., Thaci, D., Hamilton, J.D., Graham, N.M., Bieber, T., Rocklin, R., et al. Dupilumab treatment in adults with moderate-to-severe atopic dermatitis. N Engl J Med 371 (2014), 130–139.
89. 89 Thaci, D., Simpson, E.L., Beck, L.A., Bieber, T., Blauvelt, A., Papp, K., et al. Efficacy and safety of dupilumab in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical treatments: a randomised, placebo-controlled, dose-ranging phase 2b trial. Lancet 387 (2016), 40–52.
90. 90 Lopez-Ferrer, A., Vilarrasa, E., Puig, L., Secukinumab (AIN457) for the treatment of psoriasis. Expert Rev Clin Immunol 11 (2015), 1177–1188.
91. 91 Griffiths, C.E., Reich, K., Lebwohl, M., van de Kerkhof, P., Paul, C., Menter, A., et al. Comparison of ixekizumab with etanercept or placebo in moderate-to-severe psoriasis (UNCOVER-2 and UNCOVER-3): results from two phase 3 randomised trials. Lancet 386 (2015), 541–551.
92. 92 Langley, R.G., Elewski, B.E., Lebwohl, M., Reich, K., Griffiths, C.E., Papp, K., et al. Secukinumab in plaque psoriasis—results of two phase 3 trials. N Engl J Med 371 (2014), 326–338.
93. 93 Papp, K.A., Tyring, S., Lahfa, M., Prinz, J., Griffiths, C.E., Nakanishi, A.M., et al. A global phase III randomized controlled trial of etanercept in psoriasis: safety, efficacy, and effect of dose reduction. Br J Dermatol 152 (2005), 1304–1312.
94. 94 Krueger, J.G., Ferris, L.K., Menter, A., Wagner, F., White, A., Visvanathan, S., et al. Anti-IL-23A mAb BI 655066 for treatment of moderate-to-severe psoriasis: Safety, efficacy, pharmacokinetics, and biomarker results of a single-rising-dose, randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 136 (2015), 116–124.e7.
95. 95 Lebwohl, M., Psoriasis. Lancet 361 (2003), 1197–1204.
96. 96 Gordon, K.B., Langley, R.G., Gottlieb, A.B., Papp, K.A., Krueger, G.G., Strober, B.E., et al. A phase III, randomized, controlled trial of the fully human IL-12/23 mAb briakinumab in moderate-to-severe psoriasis. J Invest Dermatol 132 (2012), 304–314.
97. 97 Zaba, L.C., Suarez-Farinas, M., Fuentes-Duculan, J., Nograles, K.E., Guttman-Yassky, E., Cardinale, I., et al. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes. J Allergy Clin Immunol 124 (2009), 1022–1110 e1-395.
98. 98 D'Erme, A.M., Wilsmann-Theis, D., Wagenpfeil, J., Holzel, M., Ferring-Schmitt, S., Sternberg, S., et al. IL-36gamma (IL-1F9) is a biomarker for psoriasis skin lesions. J Invest Dermatol 135 (2015), 1025–1032.
99. 99 Guttman-Yassky, E., Lowes, M.A., Fuentes-Duculan, J., Zaba, L.C., Cardinale, I., Nograles, K.E., et al. Low expression of the IL-23/Th17 pathway in atopic dermatitis compared to psoriasis. J Immunol 181 (2008), 7420–7427.
100. 100 Chiricozzi, A., Nograles, K.E., Johnson-Huang, L.M., Fuentes-Duculan, J., Cardinale, I., Bonifacio, K.M., et al. IL-17 induces an expanded range of downstream genes in reconstituted human epidermis model. PLoS One, 9, 2014, e90284.
101. 101 Samuelov, L., Sprecher, E., Peeling off the genetics of atopic dermatitis-like congenital disorders. J Allergy Clin Immunol 134 (2014), 808–815.
102. 102 de Mare, S., van Erp, P.E., Ramaekers, F.C., van de Kerkhof, P.C., Flow cytometric quantification of human epidermal cells expressing keratin 16 in vivo after standardized trauma. Arch Dermatol Res 282 (1990), 126–130.
103. 103 He, M., Liang, P., IL-24 transgenic mice: in vivo evidence of overlapping functions for IL-20, IL-22, and IL-24 in the epidermis. J Immunol 184 (2010), 1793–1798.
104. 104 Wang, F., Lee, E., Lowes, M.A., Haider, A.S., Fuentes-Duculan, J., Abello, M.V., et al. Prominent production of IL-20 by CD68+/CD11c+ myeloid-derived cells in psoriasis: gene regulation and cellular effects. J Invest Dermatol 126 (2006), 1590–1599.
105. 105 Boniface, K., Bernard, F.X., Garcia, M., Gurney, A.L., Lecron, J.C., Morel, F., IL-22 inhibits epidermal differentiation and induces proinflammatory gene expression and migration of human keratinocytes. J Immunol 174 (2005), 3695–3702.
106. 106 Sa, S.M., Valdez, P.A., Wu, J., Jung, K., Zhong, F., Hall, L., et al. The effects of IL-20 subfamily cytokines on reconstituted human epidermis suggest potential roles in cutaneous innate defense and pathogenic adaptive immunity in psoriasis. J Immunol 178 (2007), 2229–2240.
107. 107 Ye, L., Lv, C., Man, G., Song, S., Elias, P.M., Man, M.Q., Abnormal epidermal barrier recovery in uninvolved skin supports the notion of an epidermal pathogenesis of psoriasis. J Invest Dermatol 134 (2014), 2843–2846.
108. 108 Takahashi, H., Tsuji, H., Minami-Hori, M., Miyauchi, Y., Iizuka, H., Defective barrier function accompanied by structural changes of psoriatic stratum corneum. J Dermatol 41 (2014), 144–148.
109. 109 Kawashima, J., Akiyama, M., Takizawa, Y., Takahashi, S., Matsuo, I., Shimizu, H., Structural, enzymatic and molecular studies in a series of nonbullous congenital ichthyosiform erythroderma patients. Clin Exp Dermatol 30 (2005), 429–431.
110. 110 Akiyama, T., Niyonsaba, F., Kiatsurayanon, C., Nguyen, T.T., Ushio, H., Fujimura, T., et al. The human cathelicidin LL-37 host defense peptide upregulates tight junction-related proteins and increases human epidermal keratinocyte barrier function. J Innate Immun 6 (2014), 739–753.
111. 111 Kiatsurayanon, C., Niyonsaba, F., Smithrithee, R., Akiyama, T., Ushio, H., Hara, M., et al. Host defense (Antimicrobial) peptide, human beta-defensin-3, improves the function of the epithelial tight-junction barrier in human keratinocytes. J Invest Dermatol 134 (2014), 2163–2173.
112. 112 Ong, P.Y., Ohtake, T., Brandt, C., Strickland, I., Boguniewicz, M., Ganz, T., et al. Endogenous antimicrobial peptides and skin infections in atopic dermatitis. N Engl J Med 347 (2002), 1151–1160.
113. 113 Boguniewicz, M., Leung, D.Y., Recent insights into atopic dermatitis and implications for management of infectious complications. J Allergy Clin Immunol 125 (2010), 4–15.
114. 114 Damsky, W.E., Leventhal, J.S., Khalil, D., Vesely, M.D., Craiglow, B.G., Milstone, L.M., et al. Recurrent coxsackievirus infection in a patient with lamellar ichthyosis. Pediatr Dermatol 33 (2016), e140–e142.
115. 115 Vyas, N.S., Kannan, S., N Jahnke, M., Hu, R.H., Choate, K.A., Shwayder, T.A., Congenital ichthyosiform erythroderma superimposed with chronic dermatophytosis: a report of three siblings. Pediatr Dermatol 33 (2016), e6–e9.
116. 116 Freitas, C.F., Mulinari-Brenner, F., Fontana, H.R., Gentili, A.C., Hammerschmidt, M., Ichthyosis associated with widespread tinea corporis: report of three cases. An Bras Dermatol 88 (2013), 627–630.
117. 117 van de Kerkhof, P.C.M., Griffiths, C.E.M., Reich, K., Leonardi, C.L., Blauvelt, A., Tsai, T.F., et al. Secukinumab long-trem safety experience: a pooled analysis of 10 phase II and III clinical studies in patients with moderate to severe plaque psoriasis. J Am Acad Dermatol 75 (2016), 83–98.e4.
118. 118 Cosentyx (secukinumab) prescribing information. Available at: https://www.pharma.us.novartis.com/sites/www.pharma.us.novartis.com/files/cosentyx.pdf. Accessed June 17, 2016.
119. 119 Dunbar, G.C., Kuchibhatla, R.V., Lee, G., TC-1734 (AZD3480) AAMI Clinical Study Group (USA). A randomized double-blind study comparing 25 and 50 mg TC-1734 (AZD3480) with placebo, in older subjects with age-associated memory impairment. J Psychopharmacol 25 (2011), 1020–1029.
120. 120 Lee, J.S., Lee, W.W., Kim, S.H., Kang, Y., Lee, N., Shin, M.S., et al. Age-associated alteration in naive and memory Th17 cell response in humans. Clin Immunol 140 (2011), 84–91.
121. 121 Chaudhari, U., Romano, P., Mulcahy, L.D., Dooley, L.T., Baker, D.G., Gottlieb, A.B., Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 357 (2001), 1842–1847.
122. 122 Schopf, R.E., Aust, H., Knop, J., Treatment of psoriasis with the chimeric monoclonal antibody against tumor necrosis factor alpha, infliximab. J Am Acad Dermatol 46 (2002), 886–891.
123. 123 Sofen, H., Smith, S., Matheson, R.T., Leonardi, C.L., Calderon, C., Brodmerkel, C., et al. Guselkumab (an IL-23-specific mAb) demonstrates clinical and molecular response in patients with moderate-to-severe psoriasis. J Allergy Clin Immunol 133 (2014), 1032–1040.
124. 124 Russell, C.B., Rand, H., Bigler, J., Kerkof, K., Timour, M., Bautista, E., et al. Gene expression profiles normalized in psoriatic skin by treatment with brodalumab, a human anti-IL-17 receptor monoclonal antibody. J Immunol 192 (2014), 3828–3836.
125. 125 Chiricozzi, A., Krueger, J.G., IL-17 targeted therapies for psoriasis. Expert Opin Investig Drugs 22 (2013), 993–1005.
126. 126 Griffiths, C.E., Strober, B.E., van de Kerkhof, P., Ho, V., Fidelus-Gort, R., Yeilding, N., et al. Comparison of ustekinumab and etanercept for moderate-to-severe psoriasis. N Engl J Med 362 (2010), 118–128.